![](https://hitconsultant.net/wp-content/uploads/2024/05/IMG_3501-1500x787.jpeg)
What you should know:
– Health Atroposthe pioneer in translating real-world clinical data into high-quality personalized evidence for care, today announced a $33 million Series B round following the adoption of its generative AI platform (GENEVA OSTM) by healthcare institutions, data platforms, research institutes, life sciences companies and more.
– Funding was led by Valtruis, with participation from new strategic investors including Cencora Ventures, McKesson Ventures and Merck GHI Fund, as well as existing investors Breyer Capital, Emerson Collective and Presidio Ventures.
Atropos Health: pioneering real-world evidence and AI innovations in healthcare
Founded in 2019 as a spin-out of Stanford University's “Green Button” technology, Atropos Health was created by Brigham Hyde Ph.D., Nigam Shah MBBS, Ph.D., and Saurabh Gombar MD, Ph.D., who are leaders in AI Real-world applications and research of evidence in health care. Their mission is to democratize access to high-quality, real-world evidence to improve health care decision-making and outcomes. Since its inception, Atropos Health has become a pioneer in generative AI, delivering unique user experiences like ChatRWDTM, which significantly reduces the time needed to produce high-quality, real-world, publication-quality evidence from months to minutes through Chat-based co-AI. -pilot.
With new funding, Atropos Health aims to strengthen its position in value-based care. The company's suite of evidence-generating applications supports whole-person care and value-based performance, already used by partners such as Arcadia. Atropos Health enables healthcare organizations to accelerate appropriate clinical decision-making, promoting high-value, low-cost care tailored to patients' unique physiology. To advance this mission, the company welcomes value-based care expert Mike Spadafore to its board of directors.
As part of this funding round, Atropos Health will form strategic partnerships with vertically integrated life sciences and healthcare entities. Through a collaboration with Cencora, a leading global pharmaceutical solutions organization, Atropos Health will extend its real-world evidence platform to oncology and specialty care. In the rapidly evolving field of oncology, where patient outcomes are critical, oncologists and researchers can now use the Atropos Evidence Network, comprising millions of anonymized patient records converted into high-quality evidence, to inform their decisions. Pharmaceutical customers, including Janssen Research & Development, LLC (a Johnson & Johnson company), can leverage this evidence network to drive critical R&D initiatives and accelerate the development of new treatments.
Launching in beta in Q4 2023, ChatRWD transforms the production of high-quality real-world evidence, reducing the process from months to minutes with a user-friendly chat interface designed for clinical and research purposes. While ChatRWD's speed is revolutionary, Atropos Health prioritizes accuracy and transparency of results. Built on GENEVA OS technology, ChatRWD is an LLM-agnostic framework that ensures the security and integrity of the LLM, eliminating the risk of unacceptable hallucinations in clinical evidence. A future publication will detail this approach and its advantages for generating precise evidence. The investment from this funding round will support the full launch of ChatRWD, with the potential to democratize access to high-quality, accurate, transparent and personalized real-world evidence.
Atropos Health, the developer of GENEVA OSTM, provides an operating system for rapid healthcare evidence through a robust network of real-world data. Healthcare and life sciences organizations partner with Atropos Health to address evidence gaps from bench to bedside, improving individual patient outcomes through data-driven care and accelerating research that advances medical science.
“As excitement about the application of generative AI technology in healthcare shifts from potential to practical applications, attention among providers, life sciences and other healthcare stakeholders is shifting. focuses on quality, transparency and automation backed by tangible ROI. For decades, high-quality clinical evidence has been the currency of value in health care. Atropos Health is built on investments to increase the production of high-quality, transparent and now real-time evidence that meets the standards of the clinical and research communities,” said Brigham Hyde, CEO and co-founder of Atropos Health . “This funding round, which includes several major strategic players in the healthcare ecosystem, confirms that our platform is quickly becoming the standard not only in automation and user experience, but also as a reliable quality layer between health data and necessary critical evidence. to better inform patient care, research and policy.